

From: IRBe
Sent: Thursday, January 02, 2014 9:34 AM
To: Kashyap, Rahul
Subject: 13-008891 - A study has been Approved by IRB

Principal Investigator Notification:

From: Mayo Clinic IRB
To: [John Park](#)
CC: [Rahul Kashyap](#)
[John Park](#)
[Alexander Vengerovsky](#)
Re: **IRB Application #:** [13-008891](#)
Title: Association of severe sepsis/ septic shock early resolution and in-hospital mortality among ICU patients

IRBe Protocol Version: 0.01
IRBe Version Date: 11/19/2013 11:31 PM

IRB Approval Date: 1/2/2014
IRB Expiration Date: 1/1/2017

Updated IRB expiration Date: 12/15/2019

The above referenced application is approved by expedited review procedures (45 CFR 46.110, item 5). **This approval is valid for a period of 3 years.** The Reviewer conducted a risk-benefit analysis, and determined the study constitutes minimal risk research. The Reviewer determined that this research satisfies the requirements of 45 CFR 46.111. The Reviewer approved waiver of the requirement to obtain informed consent in accordance with 45 CFR 46.116 as justified by the Investigator, and waiver of HIPAA authorization in accordance with applicable HIPAA regulations.

AS THE PRINCIPAL INVESTIGATOR OF THIS PROJECT, YOU ARE RESPONSIBLE FOR THE FOLLOWING RELATING TO THIS STUDY.

- 1) When applicable, use only IRB approved materials which are located under the documents tab of the IRBe workspace. Materials include consent forms, HIPAA, questionnaires, contact letters, advertisements, etc.
- 2) Submission to the IRB of any modifications to approved research along with any supporting documents for review and approval prior to initiation of the changes.
- 3) Submission to the IRB of all Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSO).
- 4) Compliance with Mayo Clinic Institutional Policies.

Mayo Clinic Institutional Reviewer